Introduction {#s1}
============

The purpose of enteral nutrition is to protect gastrointestinal mucosal integrity, thereby maintaining mucosal barrier function, intestinal immunity, and the normal flora \[[@R01]\]. Percutaneous endoscopic gastrostomy (PEG) allows long-term enteral feeding through a gastrostomy tube for various indications causing malnutrition in patients with normally functioning bowels \[[@R02]\].

In the literature, 30-day mortality rates reported for patients with PEG range from 2.4% to 22.5% \[[@R02]-[@R05]\]. It has been emphasized that short-term, less invasive methods like nasogastric (NG) feeding may be preferable in cases where the patient is unlikely to survive for 30 days after PEG placement \[[@R06]\]. Therefore, in this study, we aimed to identify biomarkers that may guide the decision of whether to perform the elective procedure of PEG.

Materials and Methods {#s2}
=====================

We included all patients who underwent PEG at the Erzurum Regional Hospital between January 1, 2010 and December 31, 2016. Data were collected by retrospective screening of patients' medical records and the hospital records system. Categorical descriptive data were expressed as frequency distribution and percentage; continuous variables were expressed as mean ± standard deviation and median (maximum - minimum).

Definition of infection site {#s2a}
----------------------------

Aspiration pneumonia refers to the pulmonary consequences resulting from this abnormal entry of fluid, particulate exogenous substances, or endogenous secretions into the lower airways \[[@R07]\].

The presence of the following criteria is necessary to diagnose aspiration pneumonia \[[@R08]\]: 1) infiltration in chest X-ray; 2) the presence of at least one of the major criteria (cough, sputum, fever) or at least one of the minor criteria (dyspnea, chest pain, consciousness change, consensus on physical examination, leukocyte count 12,000 and above); and 3) aspiration to be witnessed or to find a risk factor for aspiration.

PEG site infection was defined to be positive if three or more of the following criteria were observed: erythema, induration, exudate and/or purulent secretion \[[@R9]\].

Blood stream infection required one of the following: 1) recognized pathogen in the blood and pathogen not related to an infection at another site; or 2) fever, chills, or hypotension; and any of the following: 1) a common skin contaminant is isolated from at least two blood cultures drawn on separate occasions, and the organism is not related to infection at another site; 2) a common skin contaminant is isolated from blood culture in a patient with an intravascular device, and the physician institutes appropriate antimicrobial therapy; 3) a positive antigen test on blood and the organism is not related to infection at another site \[[@R10]\].

Bloodstream infection is the isolation of a bacterial or fungus originating in the blood stream of an infection at any anatomical site of the body \[[@R10]\].

Patients with mortality within 30 days and those who survived for more than 30 days after the PEG procedure were compared using the Chi-square test. Continuous variables did not meet the assumptions of parametric hypothesis and were compared with the non-parametric Kruskal-Wallis and Mann-Whitney U tests.

Receiver operating characteristic (ROC) curve analysis was used to demonstrate the predictive value of albumin, C-reactive protein (CRP), lymphocyte ratio, hemoglobin, and leukocyte number on mortality. A cut-off point was determined and its sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated. The Youden index (J = sensitivity + specificity - 1) was used to determine the cut-off point.

Kaplan-Meier (log-rank) analysis was used to identify PEG-related mortality risk factors, then a Cox regression model was applied for risk characterization (model: forward: likelihood ratio (LR) entry: 0.05 and removal: 0.10).

P \< 0.05 was accepted as statistically significant. Data were analyzed using SPSS 15.0 statistical software package.

Results {#s3}
=======

A total of 120 patients who underwent PEG were evaluated in the study. The mean age was 67.00 ± 18.00 years and median age was 72 years (range, 16 - 90 years). Seventy (58.3%) of the patients were male. The most common indication for PEG was cerebrovascular disease, present in 69 (57.5%) of the patients ([Table 1](#T1){ref-type="table"}).

###### Characteristics of Patients Who Underwent PEG

  Characteristics             Number (%)
  --------------------------- ------------
  Age                         
    \< 65                     42 (35%)
    ≥ 65                      78 (65.0%)
  Indication for PEG          
    Cerebrovascular disease   69 (57.5%)
    Neurologic disease        25 (20.8%)
    Dementia                  16 (13.3%)
    Malignancy                10 (8.3%)
  Department conducting PEG   
    Intensive care unit       43 (35.8)
    Inpatient units           77 (64.2%)

Within 14 days after PEG placement, 13 patients (10.3%) developed infection of the PEG site, six patients (5.0%) had bloodstream infections, and three patients (2.5%) developed aspiration pneumonia. The mortality rate among patients with post-PEG infection was 68.2%, significantly higher than in patients without infection (P = 0.012). The distribution of infectious agent according to infection type is presented in [Table 2](#T2){ref-type="table"}.

###### Distribution of the Microbial Agents of Infections Developed After Percutaneous Endoscopic Gastrotomy

  Infection               Agent                            Number (%)
  ----------------------- -------------------------------- ------------
  PEG site infection                                       13 (10.3%)
                          *Klebsiella spp.*                4 (30.7%)
                          *Enterococcus faecium*           2 (15.3%)
                          *Escherichia coli*               2 (15.3%)
                          *Acinetobacter baumannii*        2 (15.3%)
                          *Staphylococcus aureus*          1 (7.6%)
                          *Proteus mirabilis*              1 (7.6%)
                          *Stenotrophomonas maltophilia*   1 (7.6%)
  Bloodstream infection                                    6 (5.0%)
                          *Candida albicans*               5 (83.3%)
                          *Enterococcus faecium*           1 (16.7%)
  Aspiration pneumonia                                     3 (2.5%)
                          *Klebsiella spp.*                3 (100%)

Thirty-four patients (28.3%) died within 30 days of undergoing PEG. Of these patients, 64.4% were in the intensive care unit. Mortality was significantly higher among patients in intensive care compared to those whose PEG was performed in inpatient units (P \< 0.001). [Table 3](#T3){ref-type="table"} shows the patients' comorbid conditions and biomarker levels assessed on the day PEG was performed, grouped according to 30-day mortality.

###### Biomarker Levels and Comorbidities in Patients Based on 30-Day Mortality

                                         Deceased (n = 34)            Surviving (n = 86)          P value
  -------------------------------------- ---------------------------- --------------------------- ----------------
  Comorbid conditions                                                                             
    Diabetes mellitus                    2 (5.9%)                     8 (9.3%)                    \> 0.05\*
    Coronary artery disease              11 (32.4%)                   12 (14.0%)                  0.021\*\*
    Cerebrovascular disease              21 (61.8%)                   57 (66.3%)                  \> 0.05\*\*
    Dementia                             6 (17.6%)                    18 (20.9%)                  \> 0.05\*\*
    Malignancy                           \-                           9 (10.5%)                   \> 0.05\*
    Hypertension                         11 (32.4%)                   27 (31.4%)                  \> 0.05\*\*
    Chronic kidney failure               2 (5.9%)                     2 (2.3%)                    \> 0.05\*
  Biomarkers                                                                                      
    CRP (mg/L)                           124.5 (19.2 - 737.0)         28.6 (1.5 - 284.0)          \< 0.001\*\*\*
    Albumin (g/dL)                       2.67 (0.3 - 4.2)             2.97 (1.67 - 4.56)          0.001\*\*\*
    % neutrophil                         75.3 (38.8 - 96.5)           83.3 (29.6 - 96.3)          0.001\*\*\*
    % lymphocyte                         14.5 (1.8 - 56.1)            9.7 (2.9 - 29.1)            0.001\*\*\*
    Hemoglobin (g/dL)                    11.6 (7.3 - 18.2)            9.9 (8.0 - 15.7)            0.002\*\*\*
   Platelet count (10^3^/µL)             286,150 (26,600 - 613,000)   282,500 (23,250 -435,000)   0.060\*\*\*
    Leukocyte count (10^3^/µL)           9,258 (4,640 - 25,120)       13,240 (1,536 -43,750)      0.002\*\*\*
    INR                                  1.14 (0.85 - 1.54)           1.09 (0.9 - 1.46)           0.193\*\*\*
    Creatinine (mg/dL)                   0.6 (0.1 - 4.1)              0.6 (0.2 - 5.5)             0.470\*\*\*
  Days of hospitalization prior to PEG   13 (1 - 170)                 34 (2 - 89)                 \< 0.001\*\*\*

\*Fisher's exact test. \*\*Chi-square test. \*\*\*Mann-Whitney U test.

Analysis of the biomarkers' diagnostic power is presented in [Table 4](#T4){ref-type="table"}. CRP value was found to have the greatest diagnostic power (area under the curve: 82.5% (confidence interval: 74.9-90.2%)).

###### Evaluation of Biomarkers Using ROC Analysis

                               Cut-off value   P value    Sensitivity (%)      Specificity (%)      Positive predictive value (%)   Negative predictive value (%)
  ---------------------------- --------------- ---------- -------------------- -------------------- ------------------------------- -------------------------------
  CRP (mg/L)                   78.3            \< 0.001   85.2 (82.8 - 87.3)   74.5 (71.6 - 77.1)   76.9 (74.9 - 78.8)              83.4 (81.2 - 85.4)
  Albumin (g/dL)               2.71            0.001      75.5 (72.7 - 78.1)   61.8 (58.7 - 64.8)   66.8 (64.4 - 68.3)              71.6 (69.1 - 73.9
  \% neutrophil                75.89           0.001      82.3 (79.7 - 84.6)   53.1 (49.9 - 56.2)   63.7 (62.0 - 65.3)              75 (72.1 -77.6)
  \% lymphocyte                14.42           0.001      51.8 (48.6 - 54.9)   85.3 (82.9 - 87.4)   77.8 (75.0 - 80.5)              63.9 (62.2 - 65.4)
  Hemoglobin (g/dL)            9.94            0.002      73.8 (70.9 - 76.5)   58.9 (55.7 - 61.9)   64.2 (62.3 - 66.1)              69.2 (66.6 - 71.6)
  Leukocyte count (10^3^/µL)   10,530          0.002      67.6 (63.9 - 69.8)   66.7 (63.6 - 69.6)   67.0 (64.8 - 69.1)              66.4 (64.4 - 68.7)

The Cox regression analysis included variables which emerged as significant in Kaplan-Meier analysis: lymphocyte and neutrophil percentages, CRP, albumin, hemoglobin, leukocyte count, and coronary artery disease. CRP values ≥ 78.31 mg/L increased mortality by 8.756-fold, and albumin levels \< 2.71 g/dL increased mortality by 2.255-fold (confidence interval: 1.110 - 4.579, P = 0.024).

A graph of 30-day survival using both CRP and albumin is shown in [Figure 1](#F1){ref-type="fig"}. Patients with CRP values under 78.3 mg/L had a median survival of 28.6 days (27.3 - 30.0 days), while patients with CRP values over 78.3 mg/L had a median survival of 20.2 days (17.4 - 23.0 days). Patients with albumin levels under 2.71 g/dL had median survival of 21.3 days (18.2 - 24.5 days), whereas patients with albumin levels over 2.71 g/dL had a mean survival of 27.1 days (25.5 - 28.7 days).

![Survival graph based on CRP and albumin.](gr-10-172-g001){#F1}

Discussion {#s4}
==========

PEG allows long-term feeding via enteral nutrition for patients who are unable to take oral nutrition \[[@R11]\]. Being a surgical procedure, PEG introduces various complications. PEG-related complications are reported in 13.2-50% of patients who undergo the procedure \[[@R05], [@R12], [@R13]\]. The most important of these complications are aspiration pneumonia, esophageal perforation, bleeding, tube occlusion, anesthesia-related side effects, and infection of the wound site \[[@R11]\]. The incidence of local or life-threatening systemic infections following PEG is reported as 4-60% \[[@R14], [@R15]\]. The infection rate among patients analyzed in our study was 18.8% and most infections were at the incision site, consistent with the literature. Similar to previous studies, the infectious agents we identified were predominantly gram-negative microorganisms, but we also detected polymicrobial infections in our study \[[@R16]\]. In the literature, the 30-day mortality rate for PEG patients has been reported as 2.4-22.5% \[[@R02]-[@R05]\]. Compared to previous studies, the 30-day mortality rate in our study was high at 28.3%. This is likely related to the high mortality rate among patients who underwent PEG in intensive care (66.4%). Due to the high mortality rates and complications, our objective in the present study was to identify biomarkers that may guide the decision to perform PEG.

Albumin and CRP levels have been used in PEG patients to predict short-term mortality and detect acute conditions which may affect prognosis \[[@R04], [@R17]-[@R20]\]. Bloomberg et al found that CRP level over 10 mg/L and albumin under 3.0 g/dL was an independent risk factor for post-PEG mortality. In addition, using those cut-off points, the authors demonstrated a 20.5% mortality rate among patients with high CRP and low albumin levels \[[@R04]\]. In a similar study, the mortality rate was approximately 60% among patients with CRP over 21.5 mg/L and albumin under 3.15 g/dL \[[@R05]\]. Another study that identified CRP elevation after PEG as an independent risk factor reported a mortality rate of 18% at CRP levels over 50 mg/L. The cut-off point for low albumin level as an independent risk factor for post-PEG mortality in dementia patients was reported as 2.8 g/dL \[[@R20]\]. Cut-off points in our study were 78.3 mg/L for CRP and 2.71 g/dL for albumin. Consistent with previous studies, these biomarkers were identified as an independent risk factor for mortality, with 73.1% of the patients with high CRP/low albumin levels surviving less than 30 days post-PEG.

We determined a higher cut-off value for CRP than that reported in previous studies. This may be due to the inclusion in our study of patients in intensive care, patients on mechanical ventilators, and patients at high risk of infection. Although elevated CRP does not reflect a patient's overall condition and may be considered a limitation of the present study, we believe it is effective for our purpose because it serves as evidence of infection and indicates that PEG should be postponed.

Low albumin and high CRP levels have been reported previously as indicators of malnutrition, inflammation, and postoperative infection \[[@R04], [@R21], [@R22]\]. As PEG is not an emergent procedure, it can be deferred; authors have reported that it can be performed after an underlying acute condition is investigated. Meanwhile, nutritional support can be provided via less invasive methods such as parenteral feeding or nasogastric catheter \[[@R04]\]. Therefore, caution must be exercised when deciding when to perform PEG, as with any elective surgical intervention, especially in patients with high CRP and low albumin levels.

Conclusion {#s4a}
----------

Our results indicate that the presence of both high CRP level and low albumin level were associated with significantly higher rate of mortality (73.1%) in patients who underwent PEG. High CRP and low albumin levels undoubtedly constitute a mortality risk for all surgical procedures. Furthermore, low albumin levels are an indicator of malnutrition, which is the reason PEG is performed. However, patients who die within 30 days are not able to benefit from PEG. Therefore, guided by albumin and CRP, underlying acute conditions must be identified and alleviated. We believe that providing nutritional support by alternative routes allows the PEG procedure to be deferred until it is safer to perform.
